Tomas A Bonome from Bethesda, MD, age 47

view source

Location:

Washington, DC

Work:

Director of Business Development

Pro-Angiogenic Genes In Ovarian Tumor Endothelial Cell Isolates
view source
US Patent:

20100286237, Nov 11, 2010
Filed:

Aug 14, 2009
Appl. No.:

12/541729
Inventors:

Michael J. Birrer - Mt. Airy MD, US
Tomas A. Bonome - Washington DC, US
Anil Sood - Pearland TX, US
Chunhua Lu - Missouri City TX, US
International Classification:

A61K 31/7088
A61P 35/00
C12Q 1/68
US Classification:

514 44 A, 435 6
Abstract:

A gene profiling signature for ovarian tumor endothelial cells is disclosed herein. The gene signature can be used to diagnosis or prognosis an ovarian tumor, identify agents to treat an ovarian tumor, to predict the metastatic potential of an ovarian tumor and to determine the effectiveness of ovarian tumor treatments. Thus, methods are provided for identifying agents that can be used to treat ovarian cancer, for determining the effectiveness of an ovarian tumor treatment, or to diagnose or prognose an ovarian tumor. Methods of treatment are also disclosed which include administering a composition that includes a specific binding agent that specifically binds to one of the disclosed ovarian endothelial cell tumor-associated molecules and inhibits ovarian tumor in the subject.

Gene Expression Profile That Predicts Ovarian Cancer Subject Response To Chemotherapy
view source
US Patent:

20110178154, Jul 21, 2011
Filed:

Feb 6, 2008
Appl. No.:

12/526025
Inventors:

Michael J. Birrer - Mt. Airy MD, US
Laurent L. Ozbun - Germantown MD, US
Tomas A. Bonome - Washington DC, US
Samuel Mok - Boston MA, US
International Classification:

A61K 31/713
C40B 30/00
C12Q 1/68
G01N 33/68
C40B 30/04
C40B 40/00
A61P 35/00
US Classification:

514 44 A, 506 7, 435 612, 435 618, 436501, 506 9, 506 13
Abstract:

A gene profiling signature is disclosed herein. The gene signature can predict whether a subject with ovarian cancer will be chemorefractory, chemoresistant or chemosensitive. Thus, methods are disclosed for determining whether a subject with ovarian cancer is sensitive to treatment with a chemotherapeutic agent. Methods are also provided for increasing sensitivity to the chemotherapeutic agent if the presence of differential expression indicates that the ovarian cancer has a decreased sensitivity to chemotherapeutic agent.

Tomas A Bonome